FOSS provides four year warranty on analytical instruments with FossCare Premium service agreements
January 2, 2013
FOSS announces a new warranty and service offering to ensure that analytical instrument users enjoy uninterrupted uptime and a maximum return on their analytical investment. A four year warranty is provided as part of the new FossCare Premium Preventive Maintenance Agreement while two years warranty is provided as part of any other FossCare agreement. In [...]
Brighter near infrared light for food analysis
January 2, 2013
FOSS is participating in a research project to look at how a new, much brighter form of infrared light can be used for routine analysis in food and feed production. Infrared analysis is a widely used technology in food and feed production today. The aptly named ‘Light & Food’ project will investigate how the new [...]
Genome Interpretation Company Omicia Appoints Mike Aicher as CEO
January 2, 2013
EMERYVILLE, Calif.-- Omicia, Inc., a privately held company offering integrated solutions for interpreting human genome sequences, today announced the appointment of Mike Aicher as Chief Executive Officer and member of the company’s Board of Directors. “Martin and the outstanding Omicia team have built a truly ground-breaking genome interpretation platform with the highest levels of scientific [...]
Ametek Announces Two Technology Acquisitions
January 2, 2013
Berwyn, PA, – AMETEK, Inc. (NYSE: AME) today announced that it has completed two technology-related acquisitions: Sunpower, Inc., a privately held leader in the development of stirling cycle cryocoolers and externally heated stirling engine technology for medical, scientific, telecommunication and space applications Crystal Engineering, a privately held manufacturer of high-end, portable pressure calibrators and digital [...]
December 28, 2012
SHENZHEN, China and MOUNTAIN VIEW, Calif., -- BGI-Shenzhen ("BGI") and Complete Genomics, Inc. (Nasdaq: GNOM) ("Complete") announced today that they have obtained clearance from the Committee on Foreign Investment in the United States ("CFIUS") regarding BGI's proposed acquisition of Complete pursuant to the previously announced Agreement and Plan of Merger, dated as of September 15, [...]
December 27, 2012
SUNNYVALE, Calif., -- Cepheid (NASDAQ: CPHD) today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® CT/NG. Running on Cepheid's GeneXpert® Systems, Xpert CT/NG is a qualitative in vitro molecular diagnostic test for the detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). For the [...]
EMSL Expands Materials Testing Laboratory Capabilities
December 27, 2012
EMSL announced today the addition of Q600 SDT Simultaneous DSC-TGA, high-resolution Discovery TGA, and modulated DSC, all provided by TA Instruments. Thermal analysis includes the methods for measuring a certain parameter during the heating of a sample. Differential scanning calorimetry (DSC) where the parameter is heat flow into and out of the sample and thermo-gravimetry [...]
December 27, 2012
SAN DIEGO, -- Trovagene, Inc. (NASDAQ: TROV), a developer of transrenal molecular diagnostics, announced it has granted Duke University and Duke University Health Systems a non-exclusive license to incorporate nucleophosmin protein (NPM1) into research and clinical testing services for acute myelogenous leukemia (AML). Trovagene holds an exclusive worldwide license to U.S. patent 8,222,370 and the [...]
BD Completes Acquisition of Safety Syringes, Inc.
December 26, 2012
Franklin Lakes, NJ – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed its acquisition of Safety Syringes, Inc., a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes. The financial terms were not disclosed. The acquisition broadens BD’s [...]
Integrating matrix into 3D spheroid culture enables high throughput measurement of cell invasion
December 21, 2012
AMSBIO has announced the launch of the 3D Culture 96-Well BME* Cell Invasion Assay to address the growing need for more complete and physiologically predictive cancer invasion models. Invasive migration is a fundamental function underlying cellular processes such as angiogenesis, embryonic development, immune response, metastasis, and invasion of cancer cells. AMSBIO's new 3D Culture 96-Well [...]

